Manish Dhawan
Overview
Explore the profile of Manish Dhawan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
1424
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhawan M, Thakur N, Sharma M, Rabaan A
Biomed Pharmacother
. 2025 Mar;
185:117936.
PMID: 40056829
The antibody-mediated immune response is crucial for the development of protective immunity against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. Understanding the interaction between SARS-CoV-2 and the immune system...
2.
Singh S, Sharma A, Dhawan M, Sharma S
Indian J Crit Care Med
. 2024 Oct;
28(9):847-853.
PMID: 39360208
Aim: The objective of this study was to assess the extent of knowledge and application of central line bundles in the intensive care unit (ICU) of a tertiary care hospital...
3.
Karna R, Hans B, Nasereddin T, Chaudhary D, Dhawan M
Proc (Bayl Univ Med Cent)
. 2024 Aug;
37(5):734-741.
PMID: 39165805
Background: Nonvariceal upper gastrointestinal bleeding (NVUGIB) is a complication of dual antiplatelet therapy (DAPT) and direct oral anticoagulant therapy (DOAC). There is a lack of data comparing mechanical therapy (clips)...
4.
Ahmad T, Jin H, Dhama K, Yatoo M, Tiwari R, Bilal M, et al.
Narra J
. 2024 Mar;
2(2):e78.
PMID: 38449702
Hepatitis E virus (HEV) is an important public health problem and is responsible for both acute and chronic viral hepatitis. Public health implications of HEV are derived from its transmission...
5.
Rabaan A, Alenazy M, Alshehri A, Alshahrani M, Al-Subaie M, Alrasheed H, et al.
J Infect Public Health
. 2023 Oct;
16(11):1870-1883.
PMID: 37839310
SARS-CoV-2, responsible for COVID-19, shares 79% and 50% of its identity with SARS-CoV-1 and MERS-CoV, respectively. It uses the same main cell attachment and entry receptor as SARS-CoV-1, which is...
6.
Priyanka , Abusalah M, Chopra H, Sharma A, Mustafa S, Choudhary O, et al.
Biomed Pharmacother
. 2023 Oct;
167:115597.
PMID: 37783148
The field of nanotechnology has revolutionised global attempts to prevent, treat, and eradicate infectious diseases in the foreseen future. Nanovaccines have proven to be a valuable pawn in this novel...
7.
Verma G, Dhawan M, Saied A, Kaur G, Kumar R, Emran T
Immun Inflamm Dis
. 2023 Sep;
11(9):e1020.
PMID: 37773723
Introduction: The novel coronavirus infectious disease 2019 (COVID-19) which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a gigantic problem. The lung is the major...
8.
Kumar S, Nandan B, Chauhan R, Dhawan M, Agrawal S, Rivi S
Rev Bras Ortop (Sao Paulo)
. 2023 May;
58(2):211-221.
PMID: 37252308
Extended curettage with adjuvants of giant cell tumors of bone is associated with a lower rate of recurrence of the tumor while preserving the adjacent joint. The present study was...
9.
Karna R, Deliwala S, Ramgopal B, Asawa P, Mishra R, Mohan B, et al.
Immunotherapy
. 2023 May;
15(10):773-786.
PMID: 37190949
Combined immune checkpoint inhibitors can cause gastrointestinal adverse events. We performed a meta-analysis of pooled colonic, hepatic and pancreatic treatment-related adverse events of combined ICI. 53 trials reporting treatment-related adverse...
10.
Dhawan M, Sharma M, Emran T, Rabaan A
Int J Surg
. 2023 Apr;
109(3):504-506.
PMID: 37093079
No abstract available.